Medytox

Medytox Daewoong Pharmaceutical’s 2nd largest shareholder in the US partner

Medytox acquires shares of Daewoong Pharmaceutical’s U.S. partner Evolu, becoming the second largest shareholder

[특징주] Medytox, upper limit on news of’US Botox dispute’ agreement (general)

‘Botox War’ Medytox and Daewoong agreed to dispute with the US… Notice of bleeding again for domestic flights

[특징주] Medytox,’upper limit’ on news of’US Botox dispute’ agreement

[특징주] Medytox, intraday ceiling on news of’US Botox dispute’

[특징주] Medytox, intraday ceiling on news of’US Botox dispute’

Compensation + Loyalty + Stock… Medytox in the wake of the’Botox War’-JoongAng Ilbo

Medytox and Daewoong settle ITC litigation with three-party agreement… Domestic trial continues

Medytox and Daewoong settle ITC litigation with three-party agreement… Domestic trial continues

Daewoong Pharmaceutical, operating profit of 17 billion won last year… 62% decrease from the previous year

Daewoong Pharmaceutical’s “Meditox ITC judgment interpretation, false claims and distortions”